You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(02269.HK)合作伙伴旗下Sotrovimab獲美國FDA緊急使用授權治療新冠肺炎
阿思達克 05-31 12:29
藥明生物((02269.HK)公布,公司祝賀合作伙伴Vir Biotechnology抗新冠治療中和抗體sotrovimab獲得美國FDA授予緊急使用授權(EUA)。這也是繼去年2月藥明生物與Vir公司宣布就抗新冠中和抗體達成全球研發合作後的又一大喜訊。

Sotrovimab(VIR-7831)是由Vir公司和葛蘭素史克共同開發的一款單劑量在研單克隆抗體,用於治療輕度至中度COVID-19成人和兒科患者。臨床試驗結果顯示,Sotrovimab有助於降低高風險COVID-19患者住院或死亡風險,相關數據已披露在5月26日Vir發布的新聞稿。

藥明生物首席執行官陳智勝博士表示“在如此短的時間內實現EUA幾乎是不可能完成的任務,公司非常榮幸見證這一不可能變為現實,見證抗擊新冠疫情歷程中的里程碑。這也是藥明生物賦能合作伙伴抗擊新冠疫情最有力的證明之一。(wl/u)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account